We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging AtriCure (ATRC) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is AtriCure (ATRC - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AtriCure is one of 949 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AtriCure is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATRC's full-year earnings has moved 32.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ATRC has gained about 30.4% so far this year. In comparison, Medical companies have returned an average of 6.1%. This means that AtriCure is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX - Free Report) . The stock has returned 9.2% year-to-date.
Over the past three months, Boston Scientific's consensus EPS estimate for the current year has increased 2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AtriCure belongs to the Medical - Products industry, a group that includes 83 individual companies and currently sits at #155 in the Zacks Industry Rank. Stocks in this group have gained about 3.1% so far this year, so ATRC is performing better this group in terms of year-to-date returns. Boston Scientific is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on AtriCure and Boston Scientific as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging AtriCure (ATRC) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is AtriCure (ATRC - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AtriCure is one of 949 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AtriCure is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATRC's full-year earnings has moved 32.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ATRC has gained about 30.4% so far this year. In comparison, Medical companies have returned an average of 6.1%. This means that AtriCure is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX - Free Report) . The stock has returned 9.2% year-to-date.
Over the past three months, Boston Scientific's consensus EPS estimate for the current year has increased 2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AtriCure belongs to the Medical - Products industry, a group that includes 83 individual companies and currently sits at #155 in the Zacks Industry Rank. Stocks in this group have gained about 3.1% so far this year, so ATRC is performing better this group in terms of year-to-date returns. Boston Scientific is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on AtriCure and Boston Scientific as they attempt to continue their solid performance.